Glacier Bank to broach Texas in $476.2M Guaranty deal
Kalispell, Montana-based Glacier Bank has agreed to acquire Mount Pleasant, Texas-based Guaranty Bancorp in an all-stock deal worth roughly $476.2 million, the institutions said Tuesday.
The transaction, set to close in the fourth quarter, would give Glacier access to Texas, a coveted market the Montana bank's CEO said would represent the world's eighth-largest economy if it were an independent country.
The deal presumably will push Glacier past the $30 billion-asset threshold, infusing the Montana lender with $3.2 billion in assets, $2.1 billion in loans and $2.7 billion in deposits.
Buying Guaranty will give Glacier 33 new locations in the Dallas-Fort Worth and Houston metro areas, and east and central Texas.
Glacier CEO Randy Chesler called the acquisition 'a compelling opportunity to further expand our presence in the Southwest.'
'Guaranty fits strategically and culturally within the unique Glacier business model and will allow us to enter a complementary state with an exceptional demographic profile, strong growth prospects and a business-friendly operating environment,' Chesler said. 'This acquisition continues our long history of consistently adding high quality community banks to our proven banking model and we are very enthusiastic about the future opportunities this partnership will provide."
Glacier is unabashedly acquisitive, touting the Guaranty deal as its 27th purchase since 2000. It's also the second of this year. The Montana bank in January said it would purchase Bank of Idaho for $245.4 million. That transaction closed in May.
Once the latest deal closes, Guaranty will operate as 'Guaranty Bank & Trust, Division of Glacier Bank," Glacier said. It would be the Montana lender's 18th bank division.
'We are pleased to find a partner that emphasizes the relationship banking model that has been core to our success over many decades and through many business cycles," Guaranty CEO Ty Abston said Tuesday. 'This partnership gives Guaranty added strength, with the support of a larger balance sheet and the resources to invest in the latest technologies and products to serve our existing and future customers.'
Under Tuesday's deal, Guaranty shareholders will receive a share of Glacier stock for each Guaranty share they own. The transaction's $476. 2 million estimated value is based on Glacier's $41.58-per-share closing price from Monday.
Abston appeared to indicate Guaranty would operate with its current workforce intact.
"We will continue to grow and invest in our communities and our customers will be dealing with the same familiar faces, led by the same management team, in each of our markets,' the CEO said.
Glacier counted roughly $28.2 billion in assets when it announced its Bank of Idaho deal. Including the $1.3 billion in assets Glacier stood to gain in that acquisition, the Montana bank could reach $32.7 billion in assets when the Guaranty transaction closes.
Not all of Glacier's deals are whole-bank acquisitions. The Kalispell lender bought HTLF Bank's six-branch Montana presence last August.
Recommended Reading
WaFd to buy Luther Burbank in $654M deal to enter California
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Molina Healthcare, Inc. (MOH) Wins Major Medicaid Contracts in 4 States
We recently compiled a list of Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care provider offering government-sponsored healthcare programs like Medicaid and Medicare to low-income individuals and families across the U.S. Headquartered in Long Beach, California, Molina operates health plans in multiple states and serves millions through Medicaid, Medicare, and dual-eligible Special Needs Plans (D-SNPs). The company recently secured major Medicaid contract wins and renewals in states like Georgia, Idaho, Massachusetts, and Ohio, which will contribute to revenue growth and expand access to care. Molina Healthcare, Inc. (NYSE:MOH) also acquired ConnectiCare Holding Co., adding 140,000 members, and previously took over Bright Health's assets in California. A key strategic focus is the dual-eligible population, those covered by both Medicaid and Medicare, due to their complex needs and potential for integrated, high-quality care. Molina is developing blended service models and adjusting policy and reimbursement structures to address this growing segment. A healthcare professional wearing a health communications device discussing patient data with a colleague. Molina Healthcare, Inc. (NYSE:MOH) remains active in community engagement, such as maternal health initiatives in Texas. It's also prioritizing behavioral health and chronic condition management through updated protocols and external partnerships. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
UnitedHealth Group Incorporated (UNH) Expands Rural Care with $7M in Maternal Health Grants
We recently compiled a list of It is the largest U.S. health insurer, operating through its insurance arm (UnitedHealthcare) and health services division (Optum). It serves over 50 million people and continues to focus on transforming care delivery through value-based care, integrated services, and investments in social determinants of health. In May 2025, Stephen J. Hemsley returned as CEO, replacing Andrew Witty. The leadership shift comes amid uncertainty, with the company withdrawing its 2025 financial outlook but reaffirming its long-term goals of improving healthcare access, quality, and affordability. UNH is expanding care access, particularly for underserved and rural populations. Through the UnitedHealth Foundation, the company partnered with Cherokee Health Systems to improve rural prescription delivery. It also committed $7 million in grants to maternal and infant health, and its affordable housing-linked health investments reached $1.2 billion. A major project in Minneapolis will include 83 housing units and a new health center expected to serve 3,000 additional patients annually. For 2025, UnitedHealth Group Incorporated (NYSE:UNH) introduced 140 new Medicare Advantage plans, expanding support for chronically ill and dual-eligible populations. The Chronic Special Needs Plans (C-SNPs) will significantly increase coverage. Optum plans to serve 650,000 more patients under value-based care, leveraging AI tools to enhance coordination and preventive care. 15 States with the Best Healthcare in the US Optum is deepening its home-care services following its 2023 acquisition of LHC Group and now aims to acquire Amedisys. If approved, the deal would give Optum major market share in several states. However, the Department of Justice is reviewing the merger for potential antitrust violations. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data